Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease

NCT ID: NCT07273721

Last Updated: 2025-12-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-14
• Study Completion Date: 2026-07-31

Brief Summary

This randomized clinical trial with a cross-over design is being conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, and a total of 4-6 patients with type 2B von Willebrand disease (VWD) will participate.

The main purpose of this clinical trial is to investigate the efficacy and safety of BT200, a new drug for thrombocytopenic patients with type 2B von Willebrand disease (VWD). Based on previous studies, we expect that this drug will inhibit the breakdown of von Willebrand factor (VWF) in small doses, leading to an increase in von Willebrand factor (VWF), platelet count, and factor VIII. This should also lead to a reduced tendency to bleed.

This study will begin with an observation phase and will then proceed in two periods of approximately 64 days each:

Placebo or BT200 will be administered subcutaneously at a dose of 12 mg on the first day of the study. After that, patients will self-administer the drug at a dose of 6 mg (0.4 mL) or placebo once a week for another 4 weeks starting the following week (a total of 4 times over a period of 4 weeks). During this time, they will be asked to come to our clinic for a follow-up visit.

After a "washout phase" lasting several weeks, during which patients do not receive the study drug/placebo but are asked to record any bleeding events, the second period begins on day 64:

BT200 or placebo is administered again, depending on what the patients received in the first period. Patients therefore receive the study drug for 4 weeks and placebo for 4 weeks; which is administered when is randomized; a follow-up examination also takes place during this period.

At the end of the second period, there is another "washout phase" lasting several weeks. On day 127, the final examination takes place at the clinic, after which patients have the opportunity to participate in an extension study (to be amended).

Conditions

Von Willebrand Disease (VWD), Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Patients randomized to receive placebo first. They will receive the verum BT200 after an adequate washout period

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo for BT200

BT200

Patients randomized to receive BT200 (verum) first and placebo in the second phase after an adequate washout period.

Group Type: EXPERIMENTAL

BT200

Intervention Type: DRUG

Aptamer directed against the A1 domain of von Willebrand factor

Interventions

BT200

Aptamer directed against the A1 domain of von Willebrand factor

Intervention Type: DRUG

Placebo

Placebo for BT200

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥18 years old

2. Type 2B VWD with thrombocytopenia and a recent bleeding history (e.g. recurrent haematomas)

3. Able to comprehend and to give informed consent

4. Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures

Exclusion Criteria

1. Clinically significant medical history or ongoing chronic illness that would jeopardise the safety of the patient or compromise the quality of the data derived from his/her participation in this study

2. History of significant drug allergy or anaphylactic reactions

3. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the patient to be able to comply fully with study procedures

4. Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the patient's welfare or the integrity of the study's results

5. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical University of Vienna

OTHER

Sponsor Role: lead

Responsible Party

Christian Schoergenhofer

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Medical University of Vienna, Department of Clinical Pharmacology

Vienna, Vienna, Austria

Site Status: RECRUITING

Countries

Austria

Central Contacts

Christian Schörgenhofer, Principal Investigator, MD, PHD

Role: CONTACT

christian.schoergenhofer@meduniwien.ac.at

+43 1 40400 ext. 29810

Bernd Jilma, Subinvestigator, MD

Role: CONTACT

bernd.jilma@meduniwien.ac.at

+43 1 40400 ext. 29810

Facility Contacts

Bernd Jilma, MD

Role: primary

klin-pharmakologie@meduniwien.ac.at

+43 1 40400 ext. 29810

Other Identifiers

2024-518294-34-01

Identifier Type: CTIS

Identifier Source: secondary_id

BT200-VWD2B Version 1.1

Identifier Type: -

Identifier Source: org_study_id